Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
Emma S. Winkler, Pavlo Gilchuk, Jinsheng Yu, Adam L. Bailey, Rita E. Chen, Zhenlu Chong, Seth J. Zost, Hyesun Jang, Ying Huang, James D. Allen, James Brett Case, Rachel E. Sutton, Robert H. Carnahan, Tamarand L. Darling, Adrianus C. M. Boon, Matthias Mack, Richard D. Head, Ted M. Ross, James E. Crowe, Michael Diamond
Topics & Concepts
BiologyEffectorVirologyAntibodySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakImmunologyNeutralizing antibodyBetacoronavirusComputational biologyDiseaseInfectious disease (medical specialty)PathologyMedicineOutbreakSARS-CoV-2 and COVID-19 ResearchMonoclonal and Polyclonal Antibodies ResearchViral gastroenteritis research and epidemiology